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1. Introduction
Acute leukemia is a broad term used to identify several malignancies of immature hemato‐
poietic cells. Although, variable incidences have been reported between countries, ranging
from 46 to 57 cases by million children, it is considered the most common childhood cancer
worldwide [1]. Acute lymphoblastic leukemia (ALL) is the most frequent subtype (75%-80%
of cases; with the remaining 20-25% being of myeloid origin, AML). In ALL, B cell origin is
the most frequently diagnosed (B cell ALL) representing 83%, and T cell ALL comprises 15%
[2]. The total of ALL cases represents 30-40% of all types of pediatric cancer[3].
One of the major achievements in cancer therapy has been the increased cure rates for ALL,
from 10% in the 60s to 76-86% today, although these favorable numbers are mainly valid for
developed countries[4,5]. The improvement in ALL cure rates can be in part attributed to
the assessment of conventional prognostic factors and identification of molecular markers
associated with a better response to therapy. Suitable risk stratification has permitted a more
personalized treatment, selecting patients for receiving standard or intensified therapy,
alone or in combination with drugs against ALL specific targets, and together with an en‐
hanced supportive care have contributed to the increase in the event-free survival (EFS)
rates[4]. Conventional childhood ALL stratification is based on prognostic factors related to
characteristics of the patient (age at diagnosis) and the disease itself white blood cell (WBC)
count at diagnosis, immunophenotype of the leukemic cells, presence of known genetic fu‐
sions, numerical abnormalities or abnormal gene expression, and early response to therapy
(evaluated by morphological methods or using a more accurate measurement such as mini‐
mal residual disease (MRD) analysis) [4–6].
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From a genetic point of view, ALL is one of the best characterized malignancies. Numerical
and structural chromosomal abnormalities have been described by cytogenetic methods, flu‐
orescence in situ hybridization (FISH), polymerase chain reaction (PCR), and more recently,
by next generation sequencing. Chromosomal abnormalities are clonal markers of the ALL
blast, since the cytogenetic and molecular analyses have revealed that approximately 75% of
ALL-children present these genetic lesions [7,8]. To date, more than 200 genes have been
found participating downstream of common ALL translocations [9]; interestingly, a handful
of these genes are consistently affected in many subtypes of the disease paving the way to
better understand homeostatic lymphopoiesis and the leukemogenic process [10].
2. Signaling and transcription factors important in lymphopoiesis and
leukemogenesis
Generation of  lymphoid cells  is  a  highly ordered multi-step process that  in adult  mam‐
mals  starts  in  bone  marrow  with  the  differentiation  of  multipotent  hematopoietic  stem
cells  (HSC)  (Figure  1A).  HSCs  start  a  differentiation  pathway  in  which  the  capacity  to
form multiple  lineages  is  gradually  lost  coinciding with a  gain of  lineage specific  func‐
tions. Thus, HSCs yield multipotent progenitor cells (MPPs) still  with myeloid and lym‐
phoid  potential,  which  eventually  give  rise  to  lymphoid-primed multipotent  progenitor
(LMPP)  and early  lymphoid progenitor  (ELP)  populations,  with  a  progressive  more  re‐
strictive  lymphoid  program.  Similarly,  ELPs  generate  early  T  lineage  progenitors  (ETP)
and common lymphoid  progenitors  (CLP),  and these  populations,  although still  exhibit
high plasticity, preferentially give rise in vivo to T and B cells, respectively [11,12]. Intrin‐
sic signaling and transcriptional programs shape this differentiation pathway guiding lin‐
eage  decisions.  When  these  developmental  programs  are  abnormally  activated  or
repressed, can induce the leukemogenic process.
B and T cells are characterized by their potential to express receptors with a highly diverse
repertoire of specificities: the B and T cell receptors (BCR and TCR). This diverse specificity
is given by a recombination process termed VDJ recombination and it is the sequential as‐
sembly and testing of the BCR and TCR what defines the B/T development pathway. The
first stages (pro and pre) are characterized by recombination of the antigen binding variable
sequences (heavy and light chains for the BCR, and the β, α, γ or δ chains for the TCR)
(Figure 1B). The subsequent stages require elimination of auto-reactive clones, and only
clones selected against self-recognition become functional mature cells. Genetic and bio‐
chemical studies have shown that all forms of the BCR and TCR are required for progres‐
sion through several defined developmental checkpoints [13,14]. This is an important
concept, since it illustrates that different signaling and transcription programs are operating
through all developmental stages, and therefore, if an aberrant program is established, de‐
velopment is unable to proceed. As we will see in the following sections, the leukemic gene
fusions and other genetic abnormalities produce aberrant signaling pathways or abnormal
transcriptional activities, leading to a developmental arrest in specific stages, events that
seem to be required and characterize B and T cell ALL.
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Figure 1. Schematic drawing of the early hematopoietic development. A) HSCs (hematopoietic stem cells), MPPs
(multipotent progenitors), LMPPs (lymphoid-primed MPPs), ELPs (early lymphoid progenitors), CLPs (common lym‐
phoid progenitors), ETPs (early T lineage progenitors). Important branch points during lineage decisions are shown
with arrows. B) All B- and T-cell stages can be divided according to the main processes guiding development: receptor
assembly, tolerance, and activation. Receptor assembly stages (light gray box) in B and T cells are differentiated by the
process of VDJ recombination in the heavy (IgH) and light (IgL) chains, which are recombined in the pro-B and pre-B
stages, respectively (b and a rearrangement in DN1-3 and DN4 abT cells). B cells only rearrange heavy and light chains,
while T cells can follow two different pathways of TCR chains, ab and gd. Intimate contact between immature B /DP T
cells and the stromal cells of the bone marrow and thymus allows those receptors capable of recognizing self-antigens
to be identified and eliminated through a variety of mechanisms collectively termed "tolerance". Non-self-reactive
cells transit to the mature stage where they become functional cells that could be activated and respond to foreign
antigens. The nomenclature of each sub-stage in the mouse model is shown in black letters, e.g. A-D for B cells and
DN1–4 for T cells; the most common human nomenclature is shown in red letters. The dashed lines separating all
stages indicate checkpoints at which signaling from the pre-BCR/TCR and BCR/TCR is required for positive selection
and progression along the maturation pathway. The preBCR, preTCR, and mature receptors are also illustrated in their
respective stages. B cell development occurs in bone marrow and T cell development in the thymus.
Early developmental stages are the ones generally found compromised in human pediatric
B and T cell ALL. These stages in B cell ALL are early proB or pre-proB (before heavy-chain
recombination), preB-I (after heavy-chain recombination), and preB-II (before light-chain re‐
arrangement) (Figure 1B). These stages are also recognized by the expression of stage specif‐
ic markers, a characteristic that has helped to classify the different types of pediatric ALL. B
cells are recognized by the expression of CD19 and CD10, common B cell ALL by the expres‐
sion of the BCR (IgM) either in cytoplasm (preB-I) or membrane (preB-II), and preB-I can
also be differentiated from preB-II cells by expression of the enzyme terminal deoxynucleo‐
tidyl transferase (TdT) [10].
Genetic Markers in the Prognosis of Childhood Acute Lymphoblastic Leukemia
http://dx.doi.org/10.5772/54288
195
T cells are recognized by the expression of CD3, CD5 and CD7. Early T cells lack expression
of CD4 and CD8 (double negative or DN stages). Contrary to B cell ALL, T cell ALL clones
often express markers of more advanced stages of development (for instance double posi‐
tive stages). However, these clones also show a lack of expression or cytoplasmic TCRβ, in‐
dicating that transformation happened before rearrangement of this TCR component or just
after, and thus arguing that transformation targeted ETP/DN1 or DN3´cells [15]. The acquis‐
ition of markers of more mature cells is probably due to marker aberrant expression or leu‐
kemia-induced developmental progression in absence of the TCR signal. Although,
postnatal B cell early maturation only happens in bone marrow, T cells mature in thymus.
LMPP, ELP, CLP and ETP cells are all able to leave bone marrow in response to environ‐
mental signals and complete the T cell maturation program in thymus. Therefore, ETP/DN1
cells are normal residents of bone marrow, while double positive T cells are only found in
thymus. T cell transformation of very early populations also agrees with the predominant
presence of the T cell leukemic clone in bone marrow [15].
Limitation of lineage choice during development is regulated by a combination of signaling
pathways and transcription factors. The main receptor controlling the proB stage is the
IL-7R, which is composed of an α chain (IL-7Rα) and the common cytokine receptor G chain
(GC) [16,17]. Deletion of IL-7Rα or GC leads to developmental arrest at the early proB stage
[18–21]. IL-7 activates three major signaling pathways: 1) JAK–STAT, 2) phosphatidylinosi‐
tol 3-kinase (PI3K)–Akt and 3) Ras-Raf-Erk [22]. STAT5 (signal transducer and activator of
transcription 5) is the predominant STAT protein activated by IL-7 [22,23] and STAT5 loss
also arrest B cells at the early proB stage. Once the preBCR is expressed, it can take over
many of the functions performed by the IL-7 receptor, since the preBCR also activates the
PI3K-Akt and Ras-Raf-Erk pathways [24,25].
Downstream of IL-7 two transcription factors have been documented as the most important
for cell entry into the B cell lineage: E2A/TCF3 (immunoglobulin enhancer binding factors
E12/E47/transcription factor 3) and EBF1 (Early B cell Factor 1) [26–28]. On the other hand,
PAX5 (Paired box 5) is the more important transcription factor for B cell commitment. Loss
of E2A and EBF1 blocks entry into the B cell lineage, and loss of PAX5 redirects B cells into
other lineages [28–30]. One of the main molecular functions of PAX5 (acting together with
E2A, EBF1 and STAT5) is to allow VDJ recombination [31,32]. Ectopic expression of PAX5
and E2A allows VDJ recombination in non-B cells [45, 46]. Also, E2A, PAX5, IKZF1 and
RUNX1, among other transcription factors, are responsible for expression of the VDJ recom‐
binase (RAG) [33,34].
The most important cells that give rise to T cells are ELPs and CLPs. Although, both B and T
cells are mainly originated from them, an important genetic difference between cells prone
to the B lineage is the expression of EBF1 and PAX5, while for T cells is NOTCH1 signaling.
NOTCH1 directs progenitors into the thymus and it is the master orchestrator of T cell line‐
age entry and development [35,36]. NOTCH contains multiple epidermal growth factor
(EGF)-like repeats through which it binds its ligands DLL-1, -2, -4 (Delta-like ligand), and
Jagged-1 and -2 expressed by bone marrow and thymus stromal cells. Upon ligand binding
NOTCH1 initiates a series of proteolytic cleavage events, the first one catalyzed by the
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ADAM family of metalloproteinases and the second by the γ−secretase complex. This cleav‐
age activates NOTCH1 removing the extracellular portion and translocating to the nucleus
its intracellular region (ICN), where it becomes part of a large transcriptional activation
complex together with CSL and histone acetylase p300. Also, ICN has a C-terminal PEST do‐
main involved in regulation of NOTCH1 ubiquitylation and proteasome-mediated degrada‐
tion, therefore controlling protein turnover [35–38].
Figure 2. Schematic drawing of homeostatic and leukemic expression of acute leukemia inducing genes. Nor‐
mal (in blue) and leukemic (in red) expression of receptors, signaling proteins and transcription factors is shown along
the B and T cell development pathways. Homeostatic factors are shown to the left of the figure and their most com‐
mon modified forms in ALL are shown to the right; the upper part showing the ones compromised in T cells and the
bottom part in B cells. Developmental stages are indicated starting with the hematopoietic stem cell (HSC) and then
with the early lymphoid progenitor (ELP) and the common lymphoid progenitor (CLP) and further into the T and B cell
pathways. Of note, the proB and preB stages are the ones usually compromised in B cell ALL; in T cell ALL, marker
expression is indicative of double positive stages but TCR recombination status shows that leukemic stages most prob‐
ably belong to double negative stages. Therefore, the red line representing abnormal leukemic expression extends
from DN to DP stages in T cell development. Also, several of the transcription factors compromised in T cell ALL are not
normally expressed in these stages but ectopically expressed through the inducing genomic lesion.
NOTCH1 expression is importantly regulated by E2A [39], and is essential for activation of
genes necessary for T cell entry and early development. Indeed, NOTCH1 expression is
turned off in late stages of T cell development, forced expression of NOTCH1 in multipotent
progenitor cells direct them to the T cell lineage and controls the expression of several tran‐
scription factors important for T cell early development, e.g. HES1, Bcl11b, GATA3, TCF1,
Pu1 and RUNX1, among many more [38]. Many of these genes are required to turn off tran‐
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scriptional programs of multipotent progenitor cells or other hematopoietic lineages, or for
T cell specific functions such as recombinase expression or TCR recombination.
Some of the transcription factors drivers of T cell ALL are normally expressed in non-malig‐
nant thymocytes since they are essential regulators of T-cell ontogeny, while others are not
expressed in normal ones, but they are rather ectopically expressed by transformed cells
(Figure 2). This is contrary to B cells, in which most of the transcription factors associated
with transformation fulfill an important regulatory function (Figure 2). This observation
supports different mechanisms for the origin of B and T cell ALL. In agreement, TLX1,
TLX3, TAL1, LMO1 and LMO2 gene loci remain open during TCR recombination, increasing
the probability of aberrant rearrangements [39,40]. The identification of the signaling pro‐
teins and transcription factors compromised in B and T cell ALL has helped us to under‐
stand normal B and T cell development and its oncogenic counterpart, and as we will
emphasize in the following sections, they have also provided an important tool to classify
patients with specific genetic characteristics into risk groups matching disease prognosis.
3. Criteria for ALL risk stratification
The clinical and laboratory criteria supporting risk stratification vary among institutions,
with most groups considering as high risk the following characteristics: age ≥ 10 or <1 years
at presentation, WBC ≥ 50,000/µl, presence of extramedullary disease, T cell immunopheno‐
type, presence of adverse genetic abnormalities such as t(9;22) (BCR-ABL1), MLL gene rear‐
rangements, hypodiploidy <44 chromosomes and near haploidy. Finally, a poor response to
therapy resulting in ≥ 5% bone marrow blasts at days 15, 19, 29, 35 or 43 post-treatment is
also considered of bad prognosis [6].
All the above-mentioned prognostic factors are used to classify patients into two risk
groups, high and standard risk. For instance, it is known that increased WBC count confers
poor prognosis for B cell ALL patients and in T cell ALL, a leukocyte count greater than
100,000/µl is associated with high risk of relapse in the central nervous system. Also, pa‐
tients with hyperleukocytosis, greater than 400,000/µl, are at high risk of central nervous
system hemorrhage and pulmonary and neurological events due to leukostasis. However,
most of these risk criteria are better understood for B cell and they are not as clear for T cell
ALL patients [3]. Recently, evaluation of early response to therapy has been demonstrated
being an important parameter for treatment efficacy and disease prognosis. Based on the lat‐
ter criteria, it is possible to identify the group of patients that require augmented therapy to
improve their outcome.
3.1. Prognostic significance of treatment response
The frequency of bone marrow or circulating lymphoblasts after one week of chemotherapy
is associated with risk for relapse [41] and nowadays, this constitutes one of the most useful
prognostic factors in childhood ALL. An efficient early response to treatment is determined
by evaluating clearance rates of leukemic cells after the induction phase of treatment [42].
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This pharmacological response depends on numerous variables, including drug sensitivity /
resistance of the leukemic cells, the dosage and the ability of individual patients to metabo‐
lize and eliminate anti-leukemic drugs [43,44].
The Berlin-Frankfurt Munster (BFM) group has traditionally employed the response to pre‐
dnisone for 7 days and one dose of intrathecal methotrexate to stratify patients. Peripheral
blood blast count of 1,000/µl after prednisone treatment is used as a threshold to assign pa‐
tients into two groups, prednisone good responders (GR) and poor responders (PR). The
ALL-BMF Group demonstrated in large series of infant patients treated with effective risk-
based ALL therapy that prednisone response is a strong prognostic parameter for outcome;
75% of infants were good responders (GR) and achieved an EFS of 53% at 6 years using con‐
ventional therapy, whereas poor responder infants had an EFS of 15% [41]. The Tokyo Can‐
cer Children´s Leukemia Group also showed that B and T cell ALL patients with high blast
counts at day 8, had a 4 years EFS of 74%; in contrast, patients without blasts presented an
EFS of 89% for B and 95% for T cell ALL [43]. Thus, it is well accepted that early response to
prednisone treatment is a strong indicator of EFS [41]. However, this assessment is limited
by the low sensitivity (5-10% blasts) of microscopy-based methods of blast quantification
[45]. The morphological analysis of blasts by conventional methods easily underestimates
the presence and frequency of residual cells. PCR or flow cytometry- based methods for de‐
tecting MRD are at least 100 times more sensitive.
The common principle for all MRD assessments is that leukemogenic process results in mo‐
lecular and cellular changes, which distinguish leukemic cells from their normal counter‐
parts [46]. In patients with ALL, MRD can be monitored by flow cytometry, PCR
amplification of gene fusion transcripts, and PCR amplification of the B and T cell antigen
receptors (BCR/TCR specific VDJ recombinants). Combining information about cell size,
granularity and expression of surface and intracellular molecules, it is possible to identify by
flow cytometry a phenotypic signature characteristic of leukemic cells. Flow cytometry-
based identification of cell immunophenotypes allows the detection of one leukemic cell
among 10,000 normal cells (0.01%) [47,48]; however, these assays require high expertise for
quality results, previous knowledge of immunophenotypic profiles of normal and leukemic
cells and experience to select the best markers useful for each patient [49]. Other option to
distinguish leukemic from normal cells is the PCR screening of gene fusion transcripts, pro‐
duced by specific chromosomal translocations, among the most common of them are: BCR-
ABL1, MLL-AF4, E2A-PBX1 and ETV6-RUNX1 [50]. These genetic abnormalities can be
detected by PCR with high sensitivities ranging from 0.1- 0.001% [51]. Clonal rearrange‐
ments of the BCR and TCR genes are also useful tools for detecting MRD. Specific VDJ rear‐
rangements result in unique molecular signatures that can be detected by real-time
quantitative PCR, with a sensitivity of 0.01-0.001% [52]. The applicability of this latter meth‐
od is useful in 90% of cases, however, a leukemic blast can be associated with more than one
VDJ rearrangement during disease progression; for this reason, it is recommended to use at
least two different rearrangements as a target for each patient [53].
MRD studies revealed that many patients who achieve remission by traditional methods
harbored residual disease predisposing them to relapse [46,48].  The most immediate ap‐
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plication  of  MRD  testing  is  the  identification  of  patients  who  are  candidates  for  treat‐
ment intensification, since levels of MRD are proportional to the risk of relapse [51]. The
most  appropriate  time  for  evaluation  of  MRD  vary  between  different  groups,  for  the
ALL-BMF 95 protocol in Austria, MRD quantification by flow cytometry of bone marrow
samples  must  be  estimated  on  days  33  and  78  post-treatment.  In  the  experience  of  St.
Jude Children’s Research Hospital, the presence of 0.01% residual cells on days 19, 46, or
subsequent  time  points  during  treatment,  is  strongly  associated  with  a  high  risk  of  re‐
lapse  [54,55].  The  Children’s  Oncology Group quantifies  MRD in  bone  marrow on day
29 post-treatment, and ≥ 0.01% of MRD is associated with poor outcome [56]. The Dana-
Farber Cancer Institute ALL Consortium, considers MRD cut-off  values of 0.1% for pre‐
diction  of  5-year  relapse  hazard  [57].  Recently,  the  Italian  cooperative  group  AIEOP
identified 3 risk groups based on MRD values by flow cytometry of bone marrow sam‐
ples  on  day  15  of  treatment.  Those  risk  groups  are:  standard  (<0.01% MRD)  with  a  5-
years  cumulative  incidence  of  relapse  (CIR)  of  7.5%,  intermediate  (0.01% -  <10% MRD)
with CIR of 17.5%, and high (>10% MRD) with CIR of 47.2% [58]. MRD is also useful as
an independent predictor of second relapse in patients with ALL who had a previous re‐
lapse  and  achieved  a  second  remission  [59,60].  Notably,  the  time  of  first  relapse  and
MRD are the only 2 significant predictors of outcome in a multivariate analysis [60].
3.2. Genetic abnormalities in ALL as prognostic factors
From a genetic point of view, ALL is one of the best characterized malignancies. Numerical
and structural chromosomal abnormalities have been described by cytogenetic methods,
FISH, PCR, and more recently, by next generation sequencing. Chromosomal abnormalities
are clonal markers of the ALL blast, since the cytogenetic and molecular analyses have re‐
vealed that approximately 75% of ALL-children present these genetic lesions [7]. To date,
more than 200 genes have been found participating, downstream of common ALL transloca‐
tions. Interestingly, a handful of these genes are affected by more than one translocation,
thus supporting specific mechanisms of leukemogenesis [9].
The genetic abnormalities found in ALL are basically of two types: 1) gains or losses of one
or several chromosomes (numerical abnormalities) and 2) translocations generating gene fu‐
sions that encode proteins with novel functions (chimeric proteins), or that re-locate a gene
close to a strong transcriptional promoter causing gene overexpression. These translocations
are produced by double-strand breaks (DSB) in different chromosomes or different regions
of one chromosome, that are then recombined through non-homologous end-joining mecha‐
nisms [9,61]. These events of illegitimate recombination result in juxtaposition of normally
separated regions, relocating a gene or producing a chimeric fusion gene [3].
Several studies have demonstrated that the first genetic lesion in childhood ALL often oc‐
curs in uterus. Screening of many of the genetic lesions that characterize the ALL blast in
blood samples from Guthrie cards supports their prenatal origin. These studies have shown
the presence of the same gene fusion in blood samples collected at birth and in the leukemic
blasts at diagnosis. Thus, an intrauterine origin of MLL-AF4 has been observed in 100% of
the studied cases, ETV6-RUNX1 in 75% of cases, E2A-PBX1 in 10% of cases and a numerical
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abnormality, hyperdiploidy, in 100% of patients in one study [9]. However, it is accepted
that for all mentioned cases this first oncogenic hit is not sufficient, and additional postnatal
mutational events are required for disease initiation [62].
The known ALL genetic abnormalities have been relevant for the identification of genes in‐
volved in cancer and therefore for the insights in the biology of the leukemogenic process.
Importantly, these genetic abnormalities are a disease signature that has been an invaluable
tool for the precise disease diagnosis, prognosis and stratification into risk groups, guiding
patient management and treatment choice [63]. The Third International Workshop on Chro‐
mosomes in Leukemia was the first major study demonstrating the independent prognostic
significance of cytogenetic findings in ALL, providing data on clinical relevance of chromo‐
somal recurrent aberrations, and elucidating its molecular basis and biologic consequences
[64]. Given their importance, it is the main goal of this chapter to describe in detail the most
important genetic abnormalities in the stratification of ALL patients, highlighting aspects of
their oncogenic mechanisms, incidence and prognosis.
4. Molecular and cytogenetic subgroups in pediatric B cell ALL
As it was previously mentioned, several genetic abnormalities are characteristic of ALL and
have been relevant for the identification of genes involved in cancer and therefore have giv‐
en insights into the biology of the leukemogenic process, plus they have been an invaluable
tool for the precise disease diagnosis, prognosis and stratification into risk groups. Several
of them will be discussed in the coming sections.
4.1. BCR-ABL1 fusion
The BCR-ABL1 fusion is generated by a reciprocal translocation between sequences of the
BCR (Breakpoint cluster region; do not confuse with the B cell receptor) gene located at
22q11.23, and the ABL1 (Abelson tyrosine-protein kinase 1) gene located at 9q34.1. This
translocation generates a derivative chromosome 22 known as the Philadelphia (Ph) chro‐
mosome, and was first observed in adult patients with chronic myeloid leukemia (CML),
but later also in approximately 3-5% of pediatric ALL patients. The BCR gene contains 23
exons and encodes a 160 kD phosphoprotein of still unclear function. However, its first
exon, which is normally present in the BCR-ABL1 protein, contains a serine/threonine kin‐
ase activity and SH2 binding sites [65]. On the other hand, ABL1 is a proto-oncogene that
encodes a cytoplasmic and nuclear protein tyrosine kinase implicated in cell differentiation,
cell division, cell adhesion, and stress response [66,67]. The BCR-ABL1 fusion produces a
chimeric protein with cytoplasmic localization and oncogenic potential because retains the
catalytic domain of ABL1 fused to the BCR domain, which mediates constitutive oligomeri‐
zation of the fusion protein in the absence of physiologic activating signals, thereby promot‐
ing aberrant tyrosine kinase constitutive activity, inducing aberrant signaling and activating
multiple cellular pathways [3,68–70]. Among the signaling pathways activated contributing
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to leukemogenesis are JAK2 kinase/STAT5, MAP kinases and PI3K/Akt, which includes sev‐
eral members of the Bcl-2 family of anti-apoptotic proteins.
The  Ph chromosome detected in  CML varies  from the  one  in  ALL,  with  different  BCR
breakpoints between diseases. Two chimeric proteins with different leukemogenic poten‐
tial  are  encoded,  one  of  210  kDa prevalent  in  CML and other  of  190  kDa prevalent  in
childhood  ALL  [70,71].  In  vitro  studies  showed  that  the  190kDa  BCR-ABL  exhibits  a
greater  tyrosine  kinase  activity  than  the  210kDa form.  Thus,  this  fusion  defines  one  of
the subgroups of ALL with the worst clinical prognosis, mainly because it leads to genet‐
ic instability through the reduction in DNA repair fidelity and by generation of reactive
oxygen species, that enhance spontaneous DNA damage in tumor cells that can yield the
accumulation of additional genetic mutations [72,73].
Ph positive  childhood ALL is  associated with  older  age  at  presentation,  high leukocyte
count,  French-American-British  (FAB)  L2  morphology,  and  high  incidence  of  central
nervous  system.  Age  at  ALL presentation  influences  the  prognosis  of  this  genetic  rear‐
rangement;  patients  with  ages  ranging  from one  to  nine  years  have  a  better  prognosis
than  adolescents  and  young  adults  [70,74].  Thus,  Ph  positive  is  associated  with  a  very
high risk and poor prognosis.  Although more than 95% of patients achieve an adequate
response to induction therapy, these remissions are shallow and short-lived [6]; addition‐
ally,  these  patients  frequently  present  high  levels  of  MRD  at  the  end  of  the  induction
therapy [75]. Ph positive ALL incidence varies among different cohorts (Table 1), ranging
between 2-3% for Western European countries (Germany, Italy, Austria, Britain, Switzer‐
land) [76–78], 1-4% for American countries (USA and Mexico) [4,79] and 7-15% for East‐
ern countries (China, Taiwan, Malaysia-Singapore) [63].
Intensive research efforts were done to demonstrate the BCR-ABL1 transforming activity
in vitro  and in vivo,  as well as to describe the downstream signaling pathways and tran‐
scriptional programs affected by this translocation. These studies led to the development
of successful targeted therapy with small-molecule tyrosine kinase inhibitors (TKI),  such
as  STI571  (Imatinib  mesylate,  Gleevec®,  Novartis  Pharmaceuticals,  Basel,  Switzerland).
This  TKI  has  successfully  been  used  for  treatment  of  Ph  positive  CML patients  [69,87]
and has also permitted a better management of ALL patients. Remissions have been ach‐
ieved when Imatinib has been used either as single agent or as part of combination regi‐
mens.  In  accordance  with  COG  ALLL0031  trial  (2002-2006),  patients  who  received  a
regimen that included Imatinib achieved a 3-year EFS of 80%, which was more than the
double  of  the  EFS  rate  of  patients  treated  without  this  agent.  Although the  number  of
treated patients was small in this study, it supported that the addition of Imatinib to in‐
tensive chemotherapy can improve the outcome of Ph positive ALL children [74,87]. Ge‐
nomic  studies  have  identified  a  subtype  of  pediatric  B  cell  ALL  Ph  negative  patients
with a gene-expression profile similar to BCR-ABL1 positive ones, it is thought that these
“BCR-ABL1  like”  disease  harbors  mutations  that  deregulate  cytokine  receptor  and tyro‐
sine kinase  signaling,  this  subset  of  B  cell  ALL patients  might  also  be  benefited by the
TKI therapy [87]. “BCR-ABL1 like” group will be mentioned in a following section.
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Genetic
abnormalities
Frequency in different populations (%)
Clinical
implication
Europe America Asia
UK Medical
Research
Council
ALL97/99
[77]
ALL-
BFM90
[78,80]
UKCCG
[81]
StJChRH
[82]
Hispanics
[83]
Mexico
[84]
India
[4]
China
[85]
Malaysia-
Singapore
[86]
Numerical changes
Hyperdiploidy >50
chromosomes
38 - 31 25 41 31 - 24 -
Excellent
prognosis
with anti-
metabolite
treatment
Hypodiploidy <44
chromosomes
- - - 1-2 <1 - - - -
Poor
prognosis
Structural changes
t(1;19)(q23;p13)
E2A-PBX1
4 2 - 5
5 E2A-PBX1
or E2A-HLF
5 7 5 4
Improved
prognosis
with high-
dose
methotrexate
treatment
11q23
rearrangements
MLL
2 3 2 8 2 9 0 3 5
Poor
prognosis
t(9;22)
(q34;q11.2)
BCR-ABL1
3 2 2 2 1 4 5 17 7
Improved
early
treatment
outcome with
imatinib
t(12;21)
(p13;q22)
ETV6-RUNX1
25 22 21 25 13 9 7 19 13
Excellent
prognosis
with
asparaginase
-, non described
Table 1. Frequency of numerical and structural changes among B-ALL patients of different cohorts
4.2. E2A-PBX1 fusion
The E2A-PBX1 fusion results from the balanced translocation t(1;19)(q23;p13) or the unbal‐
anced derivative der(19)t(1;19), that involve E2A (previously described as the Immunoglo‐
bulin enhancer binding factors E12/E47, also named TCF3) and PBX1 (Pre-B cell leukemia
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transcription factor 1) genes. E2A encodes two basic helix-loop-helix (bHLH) transcription
factors, E12 and E47, through alternative splicing. Both transcription factors are immunoglo‐
bulin enhancer binding proteins involved in the regulation of immunoglobulin gene expres‐
sion [34] and in the initiation and specification of the B cell lineage [29]. PBX1 also encodes a
transcription factor (Leukemia Homeobox 1), a member of the three amino acid loop exten‐
sion (TALE) family of homeodomain proteins. PBX1 forms heterodimers with HOX family
homeodomain proteins and together with them cooperatively regulates transcription of sev‐
eral target genes according to the HOX partner [88,89]. PBX1 regulates the self-renewal po‐
tential of HSC by maintaining their quiescence state; additionally, it modulates early stages
of B-cell development. PBX1 is also important for the multi-linage potential of human em‐
bryonic stem cells (hESC) [90].
E2A-PBX1 fusion results in chimeric proteins that contain the transcriptional activation do‐
main of E2A linked to the DNA-binding domain and HOX heterodimerization domain of
PBX1. The resulting oncogenic transcription factor inappropriately activates the expression
of genes normally regulated by the PBX1-HOX heterodimers [3,91]. Among the transcrip‐
tional targets of E2A-PBX1 are WNT16 and MerTK. Since the WTN family is widely recog‐
nized to be involved in oncogenesis, it is possible that E2A-PBX1 initiates the leukemogenic
process through its potent expression of WNT16 [10,92]. MerTK is a receptor with a coupled
tyrosine kinase activity that regulates self-renewal of bone marrow precursor cells, and al‐
though MerTK is not normally expressed in committed lymphocytes, high level expression
is detected in B and T cell ALL and mantle cell lymphomas [93,94].
According to studies in different populations (Table 1), E2A-PBX1 translocation is present in
approximately 2-6% of pediatric ALL cases; however its incidence among the specific pre-B
ALL subtype (the one with cytoplasmic or membrane IgM) is approximately 25% [64,95,96].
The Total Therapy Study XIIIB at St Jude Children’s Research Hospital reported an inci‐
dence of 4.7%, with 5-year EFS of 80-90% [4,97]. On the other hand, the reported incidences
for European countries, such as Great Britain, Germany, Italy, Austria and Switzerland, is
between 2.1 and 4%, while the reported incidences for Eastern countries (Malaysia, Singa‐
pore and China) range from 4.12 to 5.37%. E2A-PBX1 has barely been detected in Guthrie
cards of B cell ALL patients, which suggests that in most cases emerges postnatally [9]. Also,
the molecular breakpoints of the E2A-PBX1 fusion in IgM positive or IgM negative cases are
generally dissimilar suggesting different origins of the disease [3,98].
Clinical features of pre-B ALL positive for E2A-PBX1, include 5 year age at presentation,
WBC count of 21-28,000/µl and pseudodiploid karyotypes [64,87,99]. Risk stratification for
E2A/PBX1 patients is controversial. It is considered of poor prognosis in adult cases, while
in children it has been reported either relatively favorable or of poor prognosis. This could
be explained in part by treatment differences; although it was initially considered of an un‐
favorable outcome, rate cures have been improved with the use of more effective therapies,
such as dosage intensification with methotrexate [64,82]. Future treatment improvements
could be achieved based on the discovery of pathways for treatment resistance of E2A-PBX1
positive cells. It has been shown that MerTK is activated by GAS6 (Growth arrest specific 6)
produced in bone marrow by mesenchymal cells, which are part of the HSC supporting
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stroma. One of the important functions regulated by GAS6 is HSC self-renewal and it is pos‐
sible that the leukemic blast becomes resistant to conventional chemotherapy due to GAS6
induced quiescence. Similar to BCR-ABL1 targeted therapy, GAS6-MerTK interaction might
be an important target for directed therapy [94].
Another translocation involving the E2A gene in ALL is t(17;19)(q22;p13), present in 1% of
children, which produces the fusion of E2A to HLF (Hepatic leukemia factor). HLF is a mem‐
ber of the bZIP family of transcription factors and the E2A-HLF fusion protein contains the
transcriptional activation domain of E2A linked to the DNA-binding and protein-protein in‐
teraction motifs of HLF. The resulting chimeric protein most probably activates the tran‐
scription of genes normally regulated by HLF. It is suggested that E2A-HLF inhibits
apoptosis through the aberrant up-regulation of SLUG and LMO2, which are anti-apoptotic
factors in normal hematopoietic progenitor cells [10,100].
4.3. MLL translocations
Myeloid/lymphoid or Mixed lineage leukemia gene (MLL, MLL1, ALL1, TRX, and HTRX) is
the human homologue of the Drosophila melanogaster trithorax gene; it is located at 11q23 and
consists of 36 exons. It encodes a 430 kDa DNA binding protein that positively regulates
HOX gene expression through methylation of lysine 4 of histone 3 (H3K4) [101]. MLL is a
large multi-domain protein, the N-terminus contains three short AT-hook motifs (ATH 1–3),
which are thought to mediate DNA binding. There are two speckled nuclear localization
sites (SNL1 and SNL2) immediately C-terminal to the ATH motifs that are followed by a
transcriptional repression domain consisting of two functional subunits, RD1 and RD2. RD1
contains a DNA methyltransferase (DMT) homology domain with a CxxC zinc-finger motif
that might recruit transcriptional repressors. RD2 recruits histone deacetylases HDAC1 and
HDAC2. There is also a plant homology domain (PHD) zinc-finger motif that might mediate
protein-protein interactions and a C-terminal SET (Su(var)3-9, enchancer-of-zeste, trithorax)
domain that possesses histone H3 lysine 4 (H3K4) methyltransferase activity [95]. Despite
RD1 and RD2, MLL is thought to be primarily a transcriptional activator due to its methyl‐
transferase activity and to the transcriptional activation domain, which recruits the tran‐
scriptional co-activator CBP (CREB-binding protein). MLL is thought to be a master gene for
epigenetic transcriptional memory regulation.
MLL in its mature form consists of two non-covalently associated subunits, an N-terminal
320 kDa fragment (MLLN) and a C-terminal 180 kDa moiety (MLLC), which are both core
components of the MLL complex and result from the cleavage of nascent MLL by an aspart‐
ic protease named taspase 1. The MLLN fragment is thought to bind DNA regulatory regions
of clustered HOX genes as part of a multi-subunit complex that includes components of the
basal transcription machinery and mediate transcriptional repression of HOX genes. How‐
ever, in the presence of MLLC, the MLLN complex can lead to transcriptional activation. The
MLLC subunit contains the SET motif and associates with at least four proteins that modify
chromatin for efficient transcription through methylation, acetylation and nucleosome re‐
modeling processes [101,102]. MLL gene is ubiquitously expressed in haematopoietic cells
including stem and progenitor populations, and HOX genes are direct targets of MLL dur‐
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ing development [7,95,102]. Also, MLL is a key constituent of the mammalian DNA damage
response pathway, and it is reported that deregulation of the S-phase checkpoint mediated
by MLL aberrations contributes to the pathogenesis of human MLL positive leukemias [103].
Most MLL translocations initiate within a well-characterized 8.3 kb breakpoint cluster region
that encompasses exons 5-11. This region is AT-rich, contains Alu, LINE, and MER repeti‐
tive sequences, putative DNA topoisomerase-II cleavage recognition sites, as well as a scaf‐
fold and matrix attachment region (SAR/MAR); these elements have been proposed to play
a direct or indirect role in promoting 11q23 rearrangements [104]. The proposed mecha‐
nisms that yield MLL translocations include recombination of Alu elements, recombination
mediated by topoisomerase-II poisons, and an error prone non-homologous end joining
(NHEJ) of DSB [101,104]. MLL fusions are diverse, since it has been found in more than 70
different translocations with numerous partner genes. The most frequent are AF4, AF9, ENL,
AF10, ELL and AF6. MLL-AF4 results from the translocation t(4;11)(q21;q23) that is common‐
ly found in patients younger than one year of age (infant ALL), while MLL-AF9 is generated
by the translocation t(9;11)(p22;q23) that is more frequently seen in secondary, therapy-in‐
duced malignancies. Although infrequent, other type of rearrangement involving MLL is the
partial tandem amplification [7].
All MLL fusions encode proteins that share a common transcriptional regulator function ca‐
pable of regulating HOX genes expression. Some of the MLL fusion partners are themselves
chromatin modifiers that function in histone acetylation, whereas other fusion partners can
recruit histone methyl-transferases, such as DOT1; methylation at lysine 79 of histone H3
catalyzed by DOT1 has been recognized as a hallmark of chromatin activated by MLL fusion
proteins [7,102,104]. MLL fusion proteins efficiently transform hematopoietic cells into leu‐
kemic cells with stem cell-like self-renewal properties [7].
MLL translocations define subgroups of high risk ALL with specific clinical and biological
characteristics associated to adverse prognosis. These subgroups include infant acute leuke‐
mia (IAL), therapy-related leukemia (a subtype of leukemia developed by patients previous‐
ly treated with etoposide after a cancer episode) and T cell ALL [102]. MLL translocations
are found in approximately 10% of all human leukemias including ALL, AML and bipheno‐
typic (mixed lineage) leukaemia, this latter one is characterized by the expression of both
myeloid and lymphoid antigens such as CD14 and CD19 in the leukemic blast [7,102]. MLL
translocations are particularly frequent (70-80%) in high risk IAL.
MLL-AF4 is one of the leukemia-inducing genetic rearrangements documented to emerge in
utero during fetal hematopoiesis. Concordant MLL-AF4 positive leukemia studies in identi‐
cal monozygotic twins demonstrated that both siblings share the same breakpoints, al‐
though the disease usually presents at different times in each twin [105]. Moreover, MLL-
AF4 can be detected in archived neonatal blood from Guthrie cards in IAL or in ALL
patients. This evidence coupled with the short period of latency observed in patients that
develop IAL, strongly suggests that some leukemia-driving gene fusions can be acquired
prenatally [9,62,95]. These observations have raised the question if in utero exposition to spe‐
cific environmental mutagens can induce MLL breakage and anomalous recombination
events. In vitro and in vivo assays have identified bioflavonoids, hormones and insecticides
Clinical Epidemiology of Acute Lymphoblastic Leukemia - From the Molecules to the Clinic206
as potential inductors of MLL aberrations [80,106–110]. Additionally, the best-known induc‐
tor of MLL aberrations is etoposide, which is a DNA topoisomerase-II inhibitor commonly
used as a chemotherapeutic agent. Etoposide induced genetic aberrations might be due to
increased concentrations of DNA topoisomerase-II DNA cleavage complex. 11q23 rear‐
rangements, particularly those that generate MLL-AF9 fusions, are found in 5-15% of secon‐
dary therapy-related leukemias [104,107,111–113].
As mentioned before, the frequency of MLL rearrangements in IAL, particularly the MLL-
AF4 fusion, is approximately 80%; however, this frequency diminishes in older children
with ALL. MLL rearrangements incidences reported from American countries ranged from
2.2-3.3%, while for European countries (Germany, Italy, Austria, UK and Switzerland) was
between 2.1-6%. The incidence of MLL rearrangements in Eastern countries (China, Taiwan,
Malaysia and Singapore) also ranged from 2.1-4.9%. The estimated 5-year EFS for patients
with MLL translocations ranged between 30-40% [4] and therefore it is considered of very
bad prognosis.
4.4. ETV6-RUNX1 fusion
RUNX1 (Runt-related transcription factor 1 and also known as AML1 or CBFα2) is a gene
that maps in 21q22.3. RUNX1 encodes a transcription factor that contains a Runt domain es‐
sential for interaction with transcription factor CBFβ and for DNA binding [114]. The
RUNX1-CBFβ heterodimer is a master regulator of early hematopoietic genes transcription.
ETV6 (E-Twenty-Six, also named TEL), is localized in 12p13.1, belongs to the ets transcrip‐
tion factor family, and contains two major domains: ETS and helix-loop-helix (HLH). ETV6
participates in fetal hematopoiesis of all lineages [115,116]. A substantial proportion (7-25%
of children and 2% of adults, Table 1) of ALL patients present the ETV6/RUNX1 fusion as a
result of the translocation t(12;21)(p13;q21). The chimeric protein from this fusion contains
the N-terminal region of ETV6 fused to almost all RUNX1, including the Runt domain. The
ETV6 fragment losses the DNA binding domain but retains the protein binding domain that
interacts with cellular proteins with transcriptional repression activity, N-CoR and mSin3a,
producing stable repression complexes at the promoters of RUNX1 target genes. mSin3a
transcriptional repressor function is due to a histone deacetylase activity(HDAC) [10] but
the ETV6-RUNX1 fusion has additional repressor functions through sequestration of tran‐
scriptional complexes and competitive inhibition of the wild-type ETV6 activity [10,116].
Several abnormalities secondary to ETV6-RUNX1 fusion have been detected, such as ETV6
loss, ETV6/RUNX1 duplication and extra copies of RUNX1 originated by trisomy 21. Recent‐
ly, it has been described that ETV6 loss occurs postnatally in more mature cells than the
ETV6-RUNX1 fusion. Analysis of this deletion revealed an unexpected similarity with SINE
and LINE retrotransposons, suggesting their participation in this loss of heterozygosity-like
mechanism of ETV6 loss. These findings are consistent with Greaves´ double hit model of
leukemogenesis for this subtype of ALL [117].
ETV6/RUNX1 positive patients have been defined as a group with excellent outcome at 5
years follow-up, which cannot be identified by standard prognostic features [118,119]. In
several studies based on different populations, this subgroup represented about 25% of cas‐
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es with B cell precursor immunophenotype [120]; and this genetic marker could also be
found in T cell ALL [81]. Other studies support different incidence rates for ETV6/RUNX1
fusions depending on ethnicity and geographic origin [83,85,121,122] (Table 1). In particular,
the lowest frequencies have been described for Hispanic [83,121] and Oriental patients
[85,123], compared to patients from West Europe and the United States. Given this differ‐
ence, further studies should be conducted looking for environmental and genetic etiologic
factors, including exposure to leukemogenic agents, analysis of predisposition genes associ‐
ated to ALL and genetic ancestry in different populations.
Several studies have supported that ETV6-RUNX1 positive patients have an excellent out‐
come in clinical trials after treatment with corticosteroids, vincristine, and asparaginase [82].
Nevertheless, ETV6/RUNX1 has been considered as a non-significant prognostic factor in
other studies, since this fusion has been found in relapsed patients [124,125]. In spite of their
excellent initial treatment response, and favorable short-term outcome, up to 24% of patients
relapse [124], and this usually occurs in patients out of treatment, often several years after
cessation of treatment and occasionally as long as 10 to 20 years later [125]. Efforts have been
made for obtaining a better understanding about the origin of relapses in this group of ALL
patients. Analyses of copy number abnormalities (CNAs) have provided evidence that
ETV6-RUNX1 positive patients have an average of 6 CNAs at diagnosis, with increasing
abundance of these CNAs at relapse, and the genes involved in CNAs usually include cell
cycle regulator genes [125,126].
The clonal origin of relapse has been investigated comparing CNA profiles from matched
ETV6/RUNX1 positive patients at diagnosis and relapse. Genes associated with cell cycle
control (cyclin-dependent kinase inhibitors CDKN2A, CDKN2B, CCNC) were found deleted
in relapsed patients. As a novel finding, trisomy 16 was observed as a recurrent abnormali‐
ty, although its significance is presently unknown [125]. A model of abnormalities acquisi‐
tion from diagnosis to relapse has been proposed; mutations detected recurrently or known
to be involved in a leukemogenic pathway were classified as driver mutations, while muta‐
tions defined as non-recurrent or without a known function in leukemogenesis were consid‐
ered passenger mutations. Four genetic profiles have been proposed with this analysis: 1)
diagnosis and relapse clones with the same abnormalities; 2) relapse clones with acquired
extra driver mutations; 3) relapse clones with losses and gains of driver mutations and 4)
relapse clones without all original CNAs but with a novel profile of genetic alterations [125].
At least 3 of these groups support that clones present at diagnosis are responsible for relap‐
ses occurring months or years after treatment cessation. In one patient with a remission last‐
ing 119 months a backtracking FISH analysis was performed, and a low number of leukemic
subclone was identified at presentation whose genotype matched that observed in the re‐
lapse clone. This patient showed clonal diversity at diagnosis and the relapse subclone prob‐
ably remained due to active mechanisms of chemotherapy resistance and quiescence. The
authors suggested that this case of relapse represents an effect of a dormant clone with low
proliferative capacity and associated drug insensitivity rather than a mutation-induced re‐
sistance effect [125]. This patient might exemplify the genetic variation sometimes observed
between initiating and relapse clones. Thus, this study argues that evolutionary genetic
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changes between the leukemic blast at presentation and relapse most probably are due to
the frequency and intrinsic genetic characteristics of the relapsed clone.
More  recently,  it  has  been  shown  that  genes  associated  with  glucocorticoid  mediated
apoptosis  could  be  deleted  in  ETV6/RUNX1  relapsed  patients.  One  of  the  most  altered
genes is  the Bcl2  modifying factor  (BMF),  whose deletion is  often detected at  diagnosis
and relapse. The glucocorticoid receptor NR3C1, and genes of the mismatch repair path‐
ways are also deleted, but this was only observed at relapse. All these genes participate
in  apoptosis  induced by  gluococorticoids,  supporting  that  a  drug resistance  mechanism
could contribute to the episode of leukemia relapse, e.g. BMF deletions leading to surviv‐
al  of  a  specific  leukemic clone after  gluococorticoid treatment  [126].  This  information is
relevant  for  future  evaluation  of  ETV6/RUNX1  patients  and  perhaps  this  genetic  lesion
should be diagnosed in ALLs together with BMF, NR3C1 and other CNAs as a guide for
novel treatment approaches.
4.5. Hyperdiploidy
Hyperdiploidy  with  51-65  chromosomes  is  also  a  frequent  abnormality,  25-41% of  ALL
patients  present  this  numerical  aberration [10,83,85]  and are generally associated with a
favorable outcome (Table 1).  This includes age 3-5 years and relative low WBC count at
presentation,  B  cell  precursor  immunophenotype  [127]  and  a  5-year  EFS  estimate  of
85-95%  when  patients  are  treated  with  anti-metabolite  based  therapy  [4,127].  Leukemic
lymphoblasts in this subgroup have a high propensity to undergo apoptosis in vitro  and
in  vivo,  and accumulate  greater  quantities  of  methotrexate  and its  active  polyglutamate
metabolites  than  other  ALL subgroups.  These  features  are  probably  very  important  for
the associated good prognosis of this subtype of ALL.
High hyperdiploidy can be detected by cytogenetic analysis or flow cytometry. This latter
technique measures the DNA content of the leukemic blasts in comparison to the normal cell
pool and DNA content of 1.16 is considered as a prognostic indicator of favorable outcome.
However, it is recommended to perform additional cytogenetic studies to detect specific
chromosome gains, and discard the presence of additional genetic rearrangements, which
could also influence disease outcome. About 50% of hyperdiploid cases present additional
abnormalities as duplications of 1q or isochromosome 17q, this last abnormality confers ad‐
verse prognosis [128]. High hyperdiploidy is often characterized cytogenetically by massive
aneuploidy, originating a non-random gain of specific chromosomes, including some or all
of +X, +4, +6, +10, +14, +17, +18, and +21; trisomies and tetrasomies of other chromosomes are
also present in this group of patients [127].
In  spite  of  the  excellent  prognosis  associated  to  this  genetic  subtype,  about  25% of  the
patients  develop  adverse  events,  indicating  outcome  differences  and  genetic  subgroups
between  high  hyperdiploid  patients.  For  this  reason,  diverse  studies  have  been  per‐
formed trying to identify prognostic characteristics in these ALL patients. Based on cyto‐
genetic  studies  and  survival  analyses,  specific  trisomies  have  been  found  associated  to
prognosis.  Results  from  univariate  analyses  informed  that  gain  of  individual  chromo‐
somes 6, 4, 10 and 18 improves prognosis, in contrast, trisomy 5 confers worse prognosis
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[129–131].  Currently,  the  Children's  Cancer  Group  (CCG)  and  the  Pediatric  Oncology
Group (POG) consider the presence of simultaneous trisomies of chromosomes 4, 10, and
17 as a favorable prognostic factor [132].
Analysis by SNP array of high hyperdiploid patients have been performed and revealed
that 80% presented CNAs, which are not detected by traditional cytogenetic methods. An
association between duplication of 1q and +5 has often been observed, and also uniparental
isodisomies of chromosomes 9 and 11, gains of chromosomes 17q and 21q, deletions and mi‐
crodeletions of ETV6, cyclin-dependent kinase inhibitor 2A (CKDN2A), PAX5 and PAN3
poly(A) specific ribonuclease subunit homolog (PAN3). Interestingly, partial deletions of AT
rich interactive domain 5B (ARID5B) were also detected [127] and polymorphisms of this
gene were recently associated to susceptibility for developing ALL, particularly associated
with the high hyperdiploid subtype [133].
ALL cases with 47-50 chromosomes have an intermediate prognosis [71], near-triploidy (69
to 81 chromosomes) [134] have a response to therapy similar to that of non-hyperdiploid,
and ALL cases with near tetraploidy (82 to 94 chromosomes) have a high frequency of T cell
immunophenotype (see T cell ALL section) and frequently harbors a cryptic ETV6-RUNX1
fusion [135]. These tetraploid leukemias, although significantly less common, have a worse
prognosis than the ones with 51-65 chromosomes. The genetic reason for this differential
prognosis is presently unclear.
4.6. Hypodiploidy
The  hypodiploid  ALL  is  defined  as  leukemic  blasts  with  less  that  46  chromosomes
and  it  is  present  in  6-7%  of  patients  with  childhood  ALL.  Three  different  subgroups
have been defined according to  the  number  of  chromosomes,  which are  also  important
for  disease  outcome:  near-haploid  ALL  (less  than  30  chromosomes),  low  hypodiploid
ALL  (33-39  chromosomes)  and  high  hypodiploid  ALL  (42-45  chromosomes).  Near-hap‐
loidy is  observed approximately  in  0.5% of  ALL cases  and it  is  most  frequently  associ‐
ated  with  females,  and  together  with  low  hypodiploidy  is  related  with  the  worst
prognosis.  Also,  children  with  near-haploidy  tend  to  be  younger  than  those  with  low
hypodiploidy  [134,136].  Most  of  the  hypodiploid  ALL  patients  belong  to  the  high  hy‐
podiploid group.
The pattern of chromosome loss in near-haploidy is not random as there is preferential re‐
tention of two copies of chromosomes 6, 8, 10, 14, 18, 21, and the sex chromosomes. In rare
cases, an apparent hyperdiploid genome is observed but the number of chromosomes re‐
sults from doubling haploid or near-haploid chromosome content. In these cases, although
there is an increased in the total number of chromosomes, this ALL is still characterized by
losses of specific chromosomes. This ALL is frequently wrongly diagnosed without a careful
cytogenetic and DNA content analysis [136], and an appropriate diagnosis is important as
near-haploidy defines a rare type of ALL associated with short remission duration and poor
prognosis. Therefore, a clear diagnosis of the total chromosome number is essential to strati‐
fy patients into the appropriate risk group.
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5. Molecular and cytogenetic subgroups in pediatric T-cell ALL
T cell ALL is a neoplastic disorder characterized by malignant transformation of early thy‐
mocytes [37]. It accounts for approximately 10-15% of pediatric ALL cases [2,37,137–139]
and tends to present clinically with high circulating blast cell counts, mediastinal masses,
and often central nervous system involvement [37,140]. Therefore, it is a high risk ALL with
a relapse rate of about 30% within the first 2 years following diagnosis [15,139]. T cell ALL is
caused by genetic alterations leading to a variety of changes that can affect cell cycle control,
unlimited self-renewal capacity, impaired differentiation and loss of sensitivity to death sig‐
nals [37]. As previously described, T cell ALL shares some chromosome rearrangements
with B cell ALL; however, about 50% of T-ALL patients have recurrent chromosomal trans‐
locations specific of this subtype. The most common chromosome abnormalities include re‐
arrangements affecting the TCR regulatory elements: juxtaposing promoter and enhancer
elements from the TCRA/D locus (T-cell receptor α/δ, 14q11) and TCRB (T-cell receptor β,
7q34) to developmentally important transcription factor genes such as homeobox genes
(TLX1, TLX3); helix-loop-helix genes (TAL1/SCL, TAL2, LYL1) or LIM-domain genes (LMO1,
LMO2) (Table 2) [15,37,139–142]. Other important genetic abnormalities frequently targeted
during malignant transformation of T cells are interstitial deletion on TAL1/SCL and
NOTCH1 point mutations (Table 2). Translocations not involving TCR loci have also been
described, relevant examples are the gene fusion CALM-AF10 and the episomal recombina‐
tion between NUP214 and ABL1 genes (Table 2) [35,141].
TCR-mediated translocations in T-ALL
Genetic
abnormalities Frequency (%) Function Outcome References
t(10;14)(q24;q11)
TLX1-TCR α/δ
t(7;10)(q35;q24)
TCR β-TLX1
4-10 Homeodomain transcription factorSpleen development Good [37,38,143]
t(1;14)(p32;q11)
TAL1-TCR α/δ 3
bHLH transcription factor
HSC survival Undefined [15,37]
t(7;9)(q34;q34.3)
TCR β-NOTCH1 <1
Transmembrane receptor
T-cell development Poor [35–38]
Non-TCR-mediated translocations and mutations in T-ALL
t(5;14)(q35;q32)
TLX3-BCL11b 20
Homeodomain transcription factor
Neural development Poor [37,38,137]
1p32 deletion SIL-
TAL1 17 bHLH transcription factor Undefined [15,37]
NOTCH1 mutations >50 Transmembrane receptorT-cell development Poor [35–38]
HSC, Hematopoietic Stem Cell
Table 2. Translocations and mutations in T-ALL
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5.1. Impaired differentiation caused by defects in transcription factors expression/
function
5.1.1. Deregulation of TLX1 and TLX3 Homeobox genes
Homeobox genes (HOX) are divided into two classes: class I HOX genes (HOXA-D) and
class two HOX genes (TLX1 and TLX3). Class II HOX genes have been extensively studied
In T cell ALL and from them TLX1 has been found activated in 4-10% of childhood T cell
ALL, most frequently by t(10;14)(q24;q11) and t(7;10)(q35;q24) chromosomal translocations
[36,37,40,137,143–145]. Both rearrangements lead to the transcriptional activation of TLX1
gene by re-location of TLX1 coding sequences under the transcriptional control of the TCR
regulatory sequences (Table 2) [36,37,40,137]. TLX1 is not normally expressed in healthy T
cells. Interestingly, overexpression of TLX1 has also been observed in absence of known
translocations, suggesting that other mechanisms of up-regulation are involved. Epigenetic
changes mediated by promoter demethylation can also lead to TLX1 aberrant expression
[36,137,145]. TLX1+ T cells are virtually all arrested at a developmental stage phenotypically
similar to the early cortical (CD1+) CD4+CD8+ “double-positive” stage of thymocyte devel‐
opment (early cortical thymocytes) [40]. However, these leukemic T cells lack preTCR ex‐
pression suggesting that the oncogenic event occurred very early in development (probably
to ETP/DN1 cells) and TLX1 aberrant expression helped the cell to bypass the first develop‐
mental checkpoints until the cells were finally arrested at the double positive stage [139].
The favorable clinical outcome of patients with this phenotype might support the arrest in
the double positive stage, since it is characterized by lack of expression of anti-apoptotic
genes because of the tolerance and negative selection mechanisms that are at work to elimi‐
nate self-reactive T cell clones [35–37,143–145].
The cryptic chromosomal translocation t(5;14)(q35;q32) juxtaposes TLX3 to the distal region
of BCL11B producing a strong expression of TLX3, a genetic lesion present in approximately
20% of childhood T cell ALL (Table 2) [15,35–37,137,141]. Like TLX1, TLX3 is not expressed
during normal T cell development [36]. Rare variants of t(5;14) have also been reported:
t(5;14)(q32;q11) involving TRA/TRD and t(5;7)(q35;q21) involving CDK6 [35–37]. Some stud‐
ies indicated that TLX3 confers a bad response to treatment, but this is controversial since
variation has been found between different populations [139]. It is possible that the prognos‐
tic meaning of TLX3 overexpression might be influenced by the presence of additional al‐
tered oncogenes such NUP214-ABL1 or NOTCH1 [15,37].
5.1.2. Deregulation of TAL1, a basic Helix-Loop-Helix (bHLH) gene
Two different models have explained the oncogenic potential and transformation mecha‐
nism of TAL1: 1) inappropriate activation of TAL1 target genes and 2) through a dominant-
negative mechanism in which TAL1 binds to and inhibits the normal activity of the E2A
(E47)/HEB transcription factor complex. The second mechanism suggests that E2A proteins
may directly regulate cell cycle in thymocyte precursors [35,37,146]. TAL1 maps on chromo‐
some 1p32 and abnormal function of this gene is one of the most common transcriptional
defects in childhood T cell ALL (Table 2); in 17% of patients TAL1 activation is a conse‐
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quence of a cryptic interstitial deletion that generates a SIL-TAL1 fusion, and in 3% of pa‐
tients, t(1;14)(p32;q11) juxtaposes TAL1 to TCR transcriptional regulatory elements causing
its ectopic expression [37]. Ectopic TAL1 expression is associated with a maturation arrest of
thymocytes. TAL1 protein could also induce overexpression of BCL2A1, resulting in anti-
apoptotic activities in the stage of T cell development arrest and a poor response to therapy,
particularly in young children [35,37,147,148].
It is documented that TLX3 expression confers a poor response to treatment, whereas TLX1
activation is significantly associated with a better prognosis in T cell ALL. A high percentage
of cryptic abnormalities of TLX1, TLX3 and TAL1 genes (both translocations and deletions),
are mostly detected only using FISH with specific probes for each type of alteration [35]. Re‐
cently, quantitative RT-PCR and expression microarrays have permitted a better and techni‐
cally simpler T cell ALL classification based on the differential oncogene expression pattern
[35]. Most probably, these new methodologies will positively impact the outcome of T cell
ALL patients, allowing for a better disease sub-typing and assignment of treatments with
better therapeutic responses.
A novel subgroup of early T cell precursor leukemia has been reported, characterized by si‐
multaneous expression of T cell/ stem-cell/myeloid markers and very poor prognosis when
treated with standard intensive chemotherapy. Interestingly, this subgroup includes a part
of those patients with LYL1 and LMO1 overexpression [2].
5.2. Activation of the NOTCH1 signaling pathway
The first alteration described affecting NOTCH1 in T cell ALL was t(7;9)(q34;q34.3), which
couples the coding sequences of the NOTCH1 ICN to the TCR β locus. This alteration is
present in <1% of T cell ALL patients [36,38,138]. Currently, gain-of-function mutations in
NOTCH1 are reported in >50% of all T cell leukemia patients. NOTCH1 mutations are main‐
ly observed in the HD and PEST domains. Mutations in HD result in NOTCH1 constitutive
activation and cell transformation. These HD NOTCH1 mutants are observed in an average
of 44% of T cell ALL patients. The deletion of the PEST domain enhances NOTCH1 intracel‐
lular signaling and is present in 30% of patients. Both, HD and PEST mutations together are
found in 17% of cases, and have a synergistic effect on NOTCH1 activation [35,38,138].
NOTCH1 mutations are found in all developmental subtypes of T cell ALL, supporting that
these mutations might occur very early in T cell progenitors [35], and in general, they repre‐
sent a marker of poor prognosis in patients with T cell ALL (Table 2) [138]. Zhu and cols
reported that the outcome of patients with NOTCH1 mutations varies according to the con‐
comitant expression of TLX1 and/or TLX3. Patients additionally positive for TLX3 expres‐
sion, have worse prognosis than those with TLX1 expression since the latter ones tent to
show prolonged survival [138].
Glucocorticoids are normally used to treat T cell ALL patients and glucocorticoid resistance
have been mapped to NOTCH1 aberrant expression. Recently, a combination therapy with
glucocorticoids and GSIs in a mouse model of resistant to treatment T cell ALL show prom‐
ising results, arguing that NOTCH1 inhibitors in combination with traditional anti-leukemic
drugs might improve disease prognosis in patients with NOTCH1 mutations [149].
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6. New prognostic markers detected by genomic variation assays and
gene expression evaluation in childhood ALL
The previously described genetic abnormalities in ALL influence the aggressive behavior of
leukemic cells and the response to treatment in an important manner. Unfortunately, those
abnormalities are not 100% predictive of disease outcome. More recently, genome wide
analysis has identified genes associated with risk to relapse in patients with primary gene
fusions and hyperdiploidy. These studies have also found novel gene abnormalities proba‐
bly leading to altered signaling pathways and gene expression patterns in the leukemic
blast. Nowadays, many novel cryptic translocations, mutations, deletions, and abnormal ex‐
pression profiles are considered useful outcome markers in children with ALL and several
of these more common markers will be further detailed in this section.
6.1. CASP8AP2
The Caspase-8-Associated Protein 2 gene, also known as FLICE associated Huge Protein
(CASP8AP2  or  FLASH),  is  located  at  6q15.  CASP8AP2  encodes  a  protein  with  multiple
functions;  although it  has  been traditionally  recognized as  a  key mediator  of  apoptosis,
several studies have demonstrated that also participates in cell division [150], NF-kappaB
signaling  [151,152],  c-Myb  activation  [153,154],  S  phase  progression  [155],  histone  tran‐
scription and 3´-end maturation of  histone mRNAs [155–157].  CASP8AP2 interacts  with
the death-effector domain (DED) of caspase 8 and hence it plays an important regulatory
role in Fas-mediated apoptosis.
The clinical significance of CASP8AP2 was first reported in Flotho and cols study [158], in
which differences in expression levels were associated with in vivo responses to multiagent
chemotherapy. CASP8AP2 expression was analyzed in 99 patients enrolled in St Jude Total
Therapy Study XIII and patients were divided into 3 groups according to expression. Pa‐
tients with high expression levels had significantly better EFS rates and lower cumulative
incidences of relapse than those with intermediate or low CASP8AP2 expression. The pro-
apoptotic function of CASP8AP2 and its low expression in leukemic blasts from patients
with persistent MRD, suggest that this gene could be a powerful predictor of treatment re‐
sponse in childhood ALL. Furthermore, Flotho and cols [159] identified a signature of 14
genes associated with MRD, and CASP8AP2 was among the signature genes with a low lev‐
el expression. Other genes down regulated in these high risk patients were the H2A histone
family member Z (H2AFZ), budding uninhibited by benzimidazoles 3 homolog (BUB3) and
CDC28 protein kinase regulatory subunit 1B (CKS1B). All these patients showed suboptimal
responses to remission induction therapy and they eventually relapsed [159].
Analyses  of  CASP8AP2  as  a  prognostic  marker  used  for  risk  stratification  have  been
made in leukemic patients from different populations. In a cohort of 39 newly diagnosed
ALL patients enrolled in Beijing Children`s Hospital (BCH)-ALL 2003 protocol,  the bone
marrow expression of CASP8AP2  at diagnosis was an useful indicator for relapse. In the
same study,  106  patients  enrolled  in  Chinese  Children´s  Leukemia  Group (CCLG)-ALL
2008 protocol were also analyzed, and patients with low CASP8AP2  expression present‐
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ed higher  relapse  rates,  lower  relapse  free  survival  and lower  overall  survival,  in  com‐
parison to the high-expression group [160].
Biologic  basis  of  the  variation  of  CASP8AP2  expression  could  be  deletions  at  band
6q15-16.1, which are often detected in patients with T cell ALL. This abnormality results
in down regulation of CASP8AP2 expression and poor response to early treatment. In 73
T  cell  ALL samples  obtained  from patients  enrolled  in  the  multicenter  ALL-BFM 1990,
ALL-BFM 1995 and ALL-BFM 2000 protocols, deletion 6q15-16.1 was associated with un‐
favorable  MRD  levels.  Although  deletion  6q15-16.1  involves  several  genes,  CASP8AP2
was the single gene with a better association between the deletion and the less efficient
induction of apoptosis by chemotherapy [161].
The usefulness of CASP8AP2 expression as a potential marker of early response to treatment
and relapse is still controversial. Yang et. al. [157] failed to show prognostic significance for
this gene expression in a group of 78 B cell ALL and 12 T cell ALL newly diagnosed patients
enrolled in the Taiwan Pediatric Oncology Group (TPOG). Further studies should be per‐
formed in ALL children from different populations and measuring different treatment pro‐
tocols in order to clarify the prognostic significance of CASP8AP2.
6.2. IKZF1
The IKZF1 or LyF1 gene encodes Ikaros, a transcription factor located on chromosome 7p12,
whose largest transcript comprises 6 zinc finger domains in 7 exons; four of these fingers are
required for DNA binding and the other 2 for homo and heterodimeric associations with
other Ikaros family members, for example Helios and Aiolos [162].
IKZF1 encodes 11 isoforms through a mechanism of alternative splicing, each isoform con‐
taining a different set of zinc finger domains dictating differential DNA binding capabilities.
Five of these isoforms (Ik-1, Ik-2, Ik-2A, Ik-3 and Ik-3A,) are considered as “long” and func‐
tional, because they conserve at least 3 N-terminal DNA binding domains, which permit
them entering to the nucleus and presenting high transcriptional activity. The remaining iso‐
forms are referred as “short” (Ik-4, Ik-4A, Ik-5, Ik-6, Ik-7 and Ik-8) and have 2 or less N-ter‐
minal DNA binding domains. They are unable to bind DNA with high affinity, do not enter
the nucleus, therefore neither activate transcription, but retain the protein binding domains
and then the ability to form homo and heterodimers. This group might act as non-DNA-
binding dominant-negative isoforms, reducing Ikaros activity. In particular, Ik-6 is not effi‐
ciently translocated to the nucleus, resulting in null transcriptional activity [162,163].
Ikaros plays an essential role in development and differentiation of lymphoid and myeloid
lineages. It acts as a tumor suppressor and as a regulator of gene expression through a chro‐
matin remodeling function. In normal cells, long Ik-1 and Ik-2 isoforms are more expressed
than the predominantly dominant-negative isoforms, Ik-3, Ik-4, Ik-5 and Ik-6 [162,163]. Dur‐
ing alternative splicing Ikaros is susceptible to loss the amino-terminal DNA-binding do‐
main, leading to increased expression of specific isoforms, in particular Ik-6, which is
strongly associated with B and T cell ALL [164–166].
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On the other hand, SNP array analysis of B cell ALL children has revealed deletions of com‐
plete IKZF1 locus; there were also deletions of coding exons 3 through 6, resulting in Ik-6
expression in B-ALL patients. It has also detected point mutations (R111, L117fs, G158S,
H224fs, S402fs and E504fs); in particular G158 attenuates the DNA-binding activity and
might act as a dominant-negative Ikaros allele. [167]. Approximately 28% of high risk B cell
ALL patients, and 9% of unselected risk patients show IKZF1 deletions [167,168]. Deletions
in IKZF1 in unselected B cell ALL Asian patients are present in 10-15%; this incidence is sim‐
ilar to the one previously seen in Caucasian countries [85,157].
“Short” and “long” isoforms can be expressed in leukemic cells from both B and T cell ALL
patients, however, the frequency and expression levels seem to vary between specific immu‐
nophenotype and genetic subgroups [169,170]. For instance, Ph positive B cell ALL patients
tend to have higher levels of Ik-6 in contrast to Ik-1 and Ik-2 [170]. Interestingly, one study
found that IKZF1 is deleted in 84% of Ph positive B cell ALL patients, supporting its impor‐
tant role in the pathogenesis of this genetic subtype [168]. Ik-6 has also been found overex‐
pressed in patients with the MLL-AF4 fusion [171].
Regarding prognosis, there is a strong correlation between mutations, deletions in IKZF1 or
presence of non-functional Ikaros isoforms, and poor outcome in both B and T cell ALL pa‐
tients. Nevertheless, this association is independent of the presence of the BCR-ABL1 fusion,
since both Ph positive and negative patients have poor outcome when IKZF1 is altered
[167,168]. Furthermore, approximately 35% of ALL relapsed cases, this condition also con‐
tributes to chemotherapy resistance [172,173]. Events of relapse have been predicted in 79%
of non-high risk ALL patients based in both MRD and IKZF1 deletions [174]. Recently, a
novel high risk ALL subgroup called “BCR-ABL1 like” has been identified, 39% of them pre‐
sented IKZF1 deletions or mutations and they had a highly unfavorable prognosis as that
found in the Ph positive B cell ALL group. About 20% of the total of B cell ALL patients be‐
long to this “BCR-ABL1 like” subgroup [175].
6.3. JAK2
The JAK2 gene is located on 9p24 and encodes a kinase that belongs to the JAK family of
protein tyrosine kinases (JAK1, JAK2, JAK3 and TYK2). All members of the JAK family are
activated by tyrosine phosphorylation and participate in proliferation, differentiation, and
cellular migration processes after activation. Additionally, JAK2 regulates apoptosis during
hematopoiesis. After JAK2 is activated, this tyrosine phosphorylates STAT5 leading to its di‐
merization, nuclear translocation and regulation of its target genes. The JAK/STAT pathway
is the main signaling mechanism for numerous cytokines and growth factors. Mutations in
different members of the JAK family are associated with inflammatory disease, erythrocyto‐
sis and childhood ALL [176,177].
Recently, it has been shown that the mutation R683, within the JAK2 pseudokinase domain,
is present in approximately 3-4% of childhood ALL patients [178]. About 10% of high risk B
cell ALL patients are R683+, however, the incidence is increased in patients with Down syn‐
drome (18-28%) [179–181]. The incidence of JAK2 mutations is about 10% in the high-risk
“BCR-ABL1 like” group [182]. JAK2 mutations have also been observed in cell lines MHH-
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CALL4 and MUTZ5, derived from B cell ALL patients without Down syndrome [183]. JAK2
mutations in ALL are significantly associated with poor outcome and the prognosis is worse
when are associated with IKZF1 deletions; this is an important observation since it has been
estimated that 87% of high risk ALL cases harbor JAK2 mutations together with IKZF1 dele‐
tions [182].
6.4. CRLF2
The Cytokine receptor-like factor 2 or CRLF2 gene also termed thymic stromal lymphopoietin
receptor (TSLPR), encodes a type I cytokine receptor. This gene is located in the pseudoauto‐
somal region 1 (PAR1) at both sex chromosomes, X (Xp22.3) and Y (Yp11.3). CRLF2 forms a
heterodimeric receptor with IL7Rα which binds the thymic stromal lymphopoietin (TSLP)
ligand. CRLF2 plays an important role during T cell and dendritic cell development, pro‐
motes B cell survival and proliferation, and is involved in inflammation, allergic responses
and malignant transformation [183,184].
Approximately 40% of children with B cell ALL have CRLF2 cryptic genetic alterations,
which induce abnormal signaling during B cell development [178]. CRLF2 is involved in 2
types of genomic rearrangements: 1) an interstitial deletion within the PAR1 region of chro‐
mosome X or Y that places the CRLF2 gene under the transcriptional control of the P2RY8
promoter (P2RY8-CRLF2), and 2) two cryptic chromosomal translocations t(X;14)(p22; q32)
and t(Y;14)(p11;q32), both involving the locus of the B cell antigen receptor heavy chain (fu‐
sion IGH-CRLF2) [183,185,186]. PAR1 deletions seem to be more frequent than IGH-CRLF2
translocation, however some groups report that translocation is the most frequent; these ob‐
servations are still controversial. CRLF2 rearrangements are associated with aberrant over‐
expression of CRLF2 in B cell ALL patients and might contribute to the pathogenesis of the
disease [187–190]. Approximately 50% of patients with high CRLF2 expression present a
CRLF2 rearrangement. However, in a few studies, low CRLF2 expression has been detected
in ALL with the P2RY8-CRLF2 rearrangement. This low expression could result from a low
frequency of the leukemic clone with the P2RY8-CRLF2 lesion within the heterogeneous
pool of leukemic blasts, further studies will be necessary to clarify it [85,187,190].
About 5-7% of Caucasian non-selected B cell ALL patients present CRLF2 rearrangements
and overexpression. This frequency increased to 16-19% in high risk B cell ALL patients; for
this reason CRLF2 abnormalities have been associated with adverse prognosis
[85,178,183,186,189–191]. Occurrence of CRLF2 abnormalities differs among ALL popula‐
tions, this is probably influenced by the ethnic origin. Harvey and colleagues found that
35.3% of Hispanic/Latin high risk B cell ALL patients have CRLF2 rearrangements and high
expression of its protein [188], this fact could explain in part the poor response to treatment
observed in this group [178,187–190]. CRLF2 analysis by different groups have demonstrat‐
ed that rearrangements in this gene do not coexist with other non-random ALL chromoso‐
mal abnormalities [186,189,190]; except for a couple of BCR-ABL1 positive patients that
showed a high CRLF2 expression, but not genomic alterations of the gene [187].
Rearrangements and overexpression of CRLF2 and JAK2 mutations are particularly abun‐
dant in B cell ALL children with Down syndrome, coexistence of both lesions have been
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found in up to 45-60% [178,186]. For this group of patients, CRLF2 rearrangements are more
frequent than other ALL aberrations as high hyperdiploid, ETV6-RUNX1, E2A-PBX1 and
MLL-AF4. A point mutation in CRLF2 (F232C) has been identified in 9% of Down syndrome
cases leading to CRLF2 overexpression [191]; it has been proposed that this alteration could
be the first leukemogenic event in these children [178,183].
A strong  interaction  among IKZF1  deletion,  CRLF2  overexpression  and JAK2  mutations
has  been described in  B  cell  ALL.  Recent  studies  support  that  100% of  B  cell  ALL pa‐
tients  with  JAK2  mutations  have  CRLF2  overexpression,  however,  the  opposite  is  not
true. Analyses of different children ALL populations have identified coexistence of these
abnormalities:  81% of  Hispanic/Latin  patients  present  CRLF2  overexpression  and IKZF1
deletions,  and  69%  of  them  have  JAK2  mutations  [188];  in  40%  of  Caucasian  patients
with CRLF2  overexpression IKZF1  deletions have been found [189];  95% of  Chinese pa‐
tients  with  JAK2  mutations  also  present  high  CRLF2  expression  [85].  In  Dutch  children
with  Down  syndrome,  deletions  of  IKZF1  were  found  in  35%,  JAK2  mutations  in  15%
and CRLF2 overexpression in 62% of cases [192].
According to these observations, it has been speculated that IKZF1 deletion, CRLF2 overex‐
pression and JAK2 mutations collaborate during B lymphoid transformation perturbing the
normal lymphoid development. Furthermore, cooperative mutations could contribute to in‐
crease the risk of relapse and promoting therapy resistance and treatment failure. Particular‐
ly, CRLF2 alterations might be the first step in carcinogenic signaling, given that its
overexpression is associated with activation of the STAT5 pathway through tyrosine phos‐
phorylation in primary B-cell progenitors [183,189,193].
7. Conclusions
Progress in risk adapted treatment of childhood ALL can currently cure up to 80% of pa‐
tients. Prognostic factors including patient and disease characteristics as well as response to
treatment, play a key role in stratification. Through exhaustive genetic characterization of
ALL, gene fusions, point mutations, deletions and gross losses or gains of genetic material
have been associated to prognosis. Recently, gene expression and comparative genomic hy‐
bridization microarrays have identified new potential genetic markers for predicting out‐
come. These markers have been evaluated in order to recognize patients prone to relapse,
even when they present low risk characteristics by conventional parameters of risk stratifica‐
tion. Based on those studies, gene signatures, mutations and signaling pathways no previ‐
ously associated to ALL have been identified. Detected abnormalities are involved in
diverse cellular processes, as cell cycle progression, cell death, and regulation of gene ex‐
pression. These activities directly influence how the leukemic blast responds to treatment,
and have an important role in the relapse process. Novel genetic alterations that have been
associated with poor outcome in ALL patients are rearrangements/mutations that trigger
CRLF2 overexpression; JAK2 mutations; IKZF1 deletions and mutations, and down expres‐
sion of CASP8AP2. Genomic analysis of relapse leukemic clones has also been useful detect‐
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ing novel genetic abnormalities that influence the aggressive behavior of leukemic cells and
in consequence the response to treatment. Recently, new mutations have been found in pa‐
tients with high hyperdiploidy or with ETV6-RUNX1 fusion. These recent findings are im‐
portant in the stratification of these subgroups of patients. ALL is one of the best
characterized malignancies at the genetic level, and the increased survival of ALL patients in
recent years is without a doubt due to the knowledge of the genes involved in ALL etiology.
Next generation technologies and discovery of new genetic markers will keep providing a
better understanding of the disease and a more comprehensive biological frame to stratify
patients into more reliable risk groups. This knowledge will also reveal potential therapeutic
targets that could yield personalized treatments, increasing the number of cured ALL chil‐
dren with less adverse sequelae.
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